BRCA-mutated ovarian cancer

FDA hands AstraZeneca and Merck a snap OK to market Lynparza in frontline ovarian cancer, marking a new standard in treatment
Endpoints
Thu, 12/20/18 - 10:01 am
AstraZeneca
Merck
Lynparza
BRCA-mutated ovarian cancer
FDA
Mammoth Lynparza survival win puts AZ, Merck in line for $1B launch
Fierce Pharma
Sun, 10/21/18 - 11:33 pm
AstraZeneca
Merck
Lynparza
PARP inhibitors
BRCA-mutated ovarian cancer
AstraZeneca Is Focused on Lynparza’s Label Expansion in 2017
Market Realist
Mon, 07/10/17 - 11:39 am
AstraZenca
Lynparza
BRCA-mutated ovarian cancer
ovarian cancer